FLT3LG and oral cavity squamous cell carcinoma: PARPi-FL is highly stable, with a low molecular weight suitable for topical application (19), and is being evaluated in a phase 1/2 clinical trial at Memorial Sloan Kettering Cancer Center for in vivo detection of oral squamous cell carcinoma (NCT03085147) (20).